Trial Profile
A phase Ib study to evaluate the safety, pharmacokinetics and efficacy of sulfatinib in patients with both medullary and differentiated thyroid cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- 09 Nov 2015 According to a Chi-Med media release, the company plans to initiate this trial by the end of 2015.
- 09 Nov 2015 New trial record